Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry

Bodur, Hatice; Yurdakul, Fatma; ATAMAN, ŞEBNEM; Cay, Hasan; GÜRER, GÜLCAN; ÇAPKIN, ERHAN; Sezer, İLHAN; DURUÖZ, MEHMET; ALKAN MELİKOĞLU, Meltem; Rezvani, Aylin; YAĞCI, İLKER; GÖĞÜŞ, FERİDE; KAMANLI, AYHAN; Akgul, Ozgur; ÇEVİK, REMZİ

doi:10.1007/s10067-022-06145-8

Where we are in treat to target era? Predictive factors for remission and drug switching in patients with axial spondyloarthritis: a real-life evidence from BioStaR nationwide registry

Atıf İçin Kopyala

Bodur H., Yurdakul F. G., ATAMAN Ş., Cay H. F., GÜRER G., ÇAPKIN E., ...Daha Fazla

CLINICAL RHEUMATOLOGY, cilt.41, sa.7, ss.2053-2063, 2022 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 41 Sayı: 7
Basım Tarihi: 2022
Doi Numarası: 10.1007/s10067-022-06145-8
Dergi Adı: CLINICAL RHEUMATOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
Sayfa Sayıları: ss.2053-2063
Anahtar Kelimeler: Disease modifying anti rheumatic drugs, Drug switching, Remission induction, Spondyloarthritis, ANKYLOSING-SPONDYLITIS, DISEASE-ACTIVITY, INHIBITORS, THERAPY, HLA-B27
Akdeniz Üniversitesi Adresli: Evet

Özet

Objectives Factors associated with disease activity of axial spondyloarthritis (axSpA) and switching of biologic disease-modifying anti-rheumatic drugs have not been clearly defined. We aimed to evaluate clinical characteristics of patients with axSpA, factors related to remission in treat to target era and predictive factors for biologic disease-modifying anti-rheumatic drug switching.